{"protocolSection":{"identificationModule":{"nctId":"NCT03807245","orgStudyIdInfo":{"id":"2017-003871-27"},"secondaryIdInfos":[{"id":"2017","type":"NIH","link":"https://reporter.nih.gov/quickSearch/2017"}],"organization":{"fullName":"Minervax ApS","class":"OTHER"},"briefTitle":"Group B Streptococcus Vaccine in Healthy Females","officialTitle":"A Phase I, Randomised, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Safety, Tolerability and Immunogenicity of Two Doses of Group B Streptococcus Vaccine (GBS-NN/NN2 With Alhydrogel®) in Healthy Female Subjects Aged 18 to 40","acronym":"MVX0002"},"statusModule":{"statusVerifiedDate":"2020-11","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2019-01-09","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2019-10-14","type":"ACTUAL"},"completionDateStruct":{"date":"2020-05-07","type":"ACTUAL"},"studyFirstSubmitDate":"2019-01-09","studyFirstSubmitQcDate":"2019-01-15","studyFirstPostDateStruct":{"date":"2019-01-16","type":"ACTUAL"},"resultsFirstSubmitDate":"2020-11-30","resultsFirstSubmitQcDate":"2020-11-30","resultsFirstPostDateStruct":{"date":"2020-12-24","type":"ACTUAL"},"lastUpdateSubmitDate":"2021-01-30","lastUpdatePostDateStruct":{"date":"2021-02-02","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Minervax ApS","class":"OTHER"},"collaborators":[{"name":"Simbec Research","class":"INDUSTRY"}]},"oversightModule":{"oversightHasDmc":false,"isFdaRegulatedDrug":false,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"A Phase I, randomised, single centre, double-blind, placebo-controlled, parallel group study to evaluate the safety, tolerability and immunogenicity of two doses of Group B Streptococcus vaccine.","detailedDescription":"There will be 4 arms in 2 cohorts of 30 subjects. Cohort 1 will receive two 0.5 mL injections, 4 weeks apart, each consisting of 25 μg of GBS-NN and 25 μg of GBS-NN2 (24 subjects) or placebo (6 subjects). Cohort 2 (30 subjects) will receive two 0.5 mL injections, 4 weeks apart, each consisting of 50 μg of GBS-NN and 50 μg of GBS-NN2 (24 subjects) or placebo (6 Subjects). All vaccines will be adsorbed to 500 μg Al3+ as Alhydrogel®.\n\nSafety will be assessed after all subjects have completed Visit 4 (Day 8) for Cohort 1, at which point the decision will be made as to whether proceeding with administration of the doses in cohort 2 is appropriate."},"conditionsModule":{"conditions":["Group B Strep Infection"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE1"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"TRIPLE","whoMasked":["PARTICIPANT","CARE_PROVIDER","INVESTIGATOR"]}},"enrollmentInfo":{"count":60,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"GBS-NN/NN2 with Alhydrogel® 25","type":"EXPERIMENTAL","description":"GBS-NN/NN2 with Alhydrogel® 25 mcg intramuscular 2 times with 4 weeks apart","interventionNames":["Biological: GBS-NN/NN2 with Alhydrogel® 25"]},{"label":"Placebo GBS-NN/NN2 with Alhydrogel® 25","type":"PLACEBO_COMPARATOR","description":"Intramuscular injection with Alhydrogel® 2 times with 4 weeks apart","interventionNames":["Biological: Placebo GBS-NN/NN2 with Alhydrogel® 25"]},{"label":"GBS-NN/NN2 with Alhydrogel® 50","type":"EXPERIMENTAL","description":"Intramuscular GBS-NN/NN2 with Alhydrogel® injection 50 mcg 2 times with 4 weeks apart","interventionNames":["Biological: GBS-NN/NN2 with Alhydrogel® 50"]},{"label":"Placebo GBS-NN/NN2 with Alhydrogel® 50","type":"PLACEBO_COMPARATOR","description":"Intramuscular injection with Alhydrogel® 2 times with 4 weeks apart","interventionNames":["Biological: Placebo GBS-NN/NN2 with Alhydrogel® 50"]}],"interventions":[{"type":"BIOLOGICAL","name":"GBS-NN/NN2 with Alhydrogel® 25","description":"GBS-NN/NN2 with Alhydrogel® vaccine will administered to subjects intramuscular 2 times with 4 weeks apart","armGroupLabels":["GBS-NN/NN2 with Alhydrogel® 25"]},{"type":"BIOLOGICAL","name":"Placebo GBS-NN/NN2 with Alhydrogel® 25","description":"GBS-NN/NN2 with Alhydrogel® vaccine will administered to subjects intramuscular 2 times with 4 weeks apart","armGroupLabels":["Placebo GBS-NN/NN2 with Alhydrogel® 25"]},{"type":"BIOLOGICAL","name":"Placebo GBS-NN/NN2 with Alhydrogel® 50","description":"GBS-NN/NN2 with Alhydrogel® vaccine will administered to subjects intramuscular 2 times with 4 weeks apart","armGroupLabels":["Placebo GBS-NN/NN2 with Alhydrogel® 50"]},{"type":"BIOLOGICAL","name":"GBS-NN/NN2 with Alhydrogel® 50","description":"GBS-NN/NN2 with Alhydrogel® vaccine will administered to subjects intramuscular 2 times with 4 weeks apart","armGroupLabels":["GBS-NN/NN2 with Alhydrogel® 50"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Number of Participants With Treatment Emergent Adverse Events","description":"Number of Participants with Treatment Emergent Adverse Events","timeFrame":"85 days"}],"secondaryOutcomes":[{"measure":"Immunoglobulin(Ig)G Antibody Concentration","description":"Adjusted geometric mean concentration (GMC)","timeFrame":"Day 85"},{"measure":"Fold Change in Antibody Concentration","description":"Geometric mean fold change in antibody concentration from Day 1 to Day 85 for each group.","timeFrame":"Day 1 to Day 85"},{"measure":"Seroconversion Rate","description":"4-fold increase in Immunoglobulin(Ig)G antibody concentration","timeFrame":"Day 85"},{"measure":"Number of Participants With an Immune Response to First and Second Doses","description":"Number of participants with Immunoglobulin(Ig)G antibody concentration above thresholds","timeFrame":"Day 29 and Day 85"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Healthy female subjects aged 18 - 40 years.\n2. Body mass index (BMI) ≥18 and ≤30 kg/m2.\n3. Subjects weight ≥50kg and ≤100kg at screening.\n4. Able to voluntarily provide written informed consent to participate in the study.\n5. Subjects are pre-menopausal.\n6. Females of childbearing potential must have a negative pregnancy test at screening (β HCG) and prior to each dose. To prevent pregnancy female subjects of childbearing potential must take adequate contraceptive precautions for the entire duration of study participation (up to Day 85). Adequate and highly effective contraceptive precautions include:\n\n   * Established use of oral, injected or implanted hormonal methods of contraception.\n   * Placement of an intrauterine device (IUD) or intrauterine system (IUS).\n   * Barrier methods of contraception: Condom or occlusive cap (diaphragm or cervical/vault caps) with spermicidal foam/gel/film/cream/suppository.\n   * Male sterilisation (with the appropriate post-vasectomy documentation of the absence of sperm in the ejaculate). \\[For female subjects, the vasectomised male partner should be the sole partner for that subject\\].\n   * True abstinence, when this is in line with the preferred and usual lifestyle of the subject.\n\n   \\[Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception\\].\n\n   • The chosen contraception method(s) must be followed from the first dose until at least Day 85 of the study.\n7. Non-smokers for at least 3 months prior to first study vaccine administration.\n\nExclusion Criteria:\n\n1. Subjects who have received GBS-NN vaccine previously.\n2. Subjects with history or presence of significant cardiovascular disease, pulmonary, hepatic, gallbladder or biliary tract, renal, haematological, gastrointestinal, endocrine, immunologic, dermatological, neurological, psychiatric, autoimmune disease or current infection.\n3. Pregnant or lactating females.\n4. Laboratory values at screening which are deemed by the investigator to be clinically significantly abnormal.\n5. Positive drug screen for drugs of abuse or a positive alcohol urine test prior to first dosing unless there is a documented medical explanation for the positive result other than drugs of abuse (e.g., the subject has been prescribed opioids for pain).\n6. Positive for human immunodeficiency virus (HIV), hepatitis B or hepatitis C.\n7. Participation in a clinical drug study during the 90 days preceding the initial dose in this study.\n8. Any significant illness during the 4 weeks preceding check-in for this study (Day 1).\n9. Subjects with a history of allergic reactions after previous vaccination.\n10. Subjects who have received any vaccine within 30 days of screening, or who are planning to receive a vaccine up to Day 85 of the study.\n11. Subjects receiving immunosuppressive therapy in the 6 months prior to screening, taking any short-term medications including over-the-counter (OTC) preparations, within 7 days of the first dose. Chronic medications such as antihypertensives, bronchodilators, oral contraceptives or statins that do not affect the immune system, will be permitted and allowed to continue during the study at the discretion of the Investigator. Paracetamol will be permitted for the treatment of headache or other symptoms. Use of OTC vitamins and dietary supplements is allowed\n12. Subjects with tattoos at the proposed site of vaccine administration.\n13. Donation of blood or blood products within 90 days prior to vaccine administration or intending to donate blood or blood products within 90 days of the last visit.\n14. Subjects who, in the opinion of the Investigator, are unsuitable for participation in the study.","healthyVolunteers":true,"sex":"FEMALE","minimumAge":"18 Years","maximumAge":"40 Years","stdAges":["ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Geoff Kitson","affiliation":"gkitson@propharmapartners.uk.com","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"Simbec Research Limited","city":"Merthyr Tydfil","state":"Wales","zip":"CF48 4DR","country":"United Kingdom","geoPoint":{"lat":51.74794,"lon":-3.37779}}]}},"resultsSection":{"participantFlowModule":{"recruitmentDetails":"Healthy female participants aged 18 to 40 years were recruited in a Phase 1 unit from January 2019 and the study was completed by October 2019.","groups":[{"id":"FG000","title":"GBS-NN/NN2 With Alhydrogel® 25","description":"GBS-NN/NN2 with Alhydrogel® containing 25 mcg of each GBS-NN and GBS-NN2 administered by intramuscular injection 2 times with 4 weeks apart"},{"id":"FG001","title":"GBS-NN/NN2 With Alhydrogel® 50","description":"GBS-NN/NN2 with Alhydrogel® containing 50 mcg of each GBS-NN and GBS-NN2 administered by intramuscular injection 2 times with 4 weeks apart"},{"id":"FG002","title":"Placebo With Alhydrogel®","description":"Placebo (buffer with Alhydrogel®) vaccine administered by intramuscular injection 2 times with 4 weeks apart"}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"24"},{"groupId":"FG001","numSubjects":"24"},{"groupId":"FG002","numSubjects":"12"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"23"},{"groupId":"FG001","numSubjects":"24"},{"groupId":"FG002","numSubjects":"12"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"}]}]}]},"baselineCharacteristicsModule":{"groups":[{"id":"BG000","title":"GBS-NN/NN2 With Alhydrogel® 25","description":"GBS-NN/NN2 with Alhydrogel® containing 25 mcg of each GBS-NN and GBS-NN2 administered by intramuscular injection 2 times with 4 weeks apart"},{"id":"BG001","title":"GBS-NN/NN2 With Alhydrogel® 50","description":"GBS-NN/NN2 with Alhydrogel® containing 50 mcg of each GBS-NN and GBS-NN2 administered by intramuscular injection 2 times with 4 weeks apart"},{"id":"BG002","title":"Placebo With Alhydrogel®","description":"Placebo (buffer with Alhydrogel®) vaccine administered by intramuscular injection 2 times with 4 weeks apart"},{"id":"BG003","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"24"},{"groupId":"BG001","value":"24"},{"groupId":"BG002","value":"12"},{"groupId":"BG003","value":"60"}]}],"measures":[{"title":"Age, Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"Years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"29.8","spread":"5.36"},{"groupId":"BG001","value":"30.8","spread":"6.04"},{"groupId":"BG002","value":"27.3","spread":"5.53"},{"groupId":"BG003","value":"29.7","spread":"5.72"}]}]}]},{"title":"Sex: Female, Male","description":"Healthy females","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"24"},{"groupId":"BG001","value":"24"},{"groupId":"BG002","value":"12"},{"groupId":"BG003","value":"60"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"}]}]}]},{"title":"Ethnicity (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Hispanic or Latino","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"}]},{"title":"Not Hispanic or Latino","measurements":[{"groupId":"BG000","value":"24"},{"groupId":"BG001","value":"24"},{"groupId":"BG002","value":"12"},{"groupId":"BG003","value":"60"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"}]}]}]},{"title":"Race (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"American Indian or Alaska Native","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"}]},{"title":"Asian","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"}]},{"title":"Native Hawaiian or Other Pacific Islander","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"}]},{"title":"Black or African American","measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"1"}]},{"title":"White","measurements":[{"groupId":"BG000","value":"23"},{"groupId":"BG001","value":"24"},{"groupId":"BG002","value":"12"},{"groupId":"BG003","value":"59"}]},{"title":"More than one race","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"}]}]}]},{"title":"Region of Enrollment","paramType":"NUMBER","unitOfMeasure":"participants","classes":[{"title":"United Kingdom","categories":[{"measurements":[{"groupId":"BG000","value":"24"},{"groupId":"BG001","value":"24"},{"groupId":"BG002","value":"12"},{"groupId":"BG003","value":"60"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Participants With Treatment Emergent Adverse Events","description":"Number of Participants with Treatment Emergent Adverse Events","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"85 days","groups":[{"id":"OG000","title":"GBS-NN/NN2 With Alhydrogel® 25","description":"GBS-NN/NN2 with Alhydrogel® containing 25 mcg of each GBS-NN and GBS-NN2 administered by intramuscular injection 2 times with 4 weeks apart"},{"id":"OG001","title":"GBS-NN/NN2 With Alhydrogel® 50","description":"GBS-NN/NN2 with Alhydrogel® containing 50mcg of each GBS-NN and GBS-NN2 administered by intramuscular injection 2 times with 4 weeks apart"},{"id":"OG002","title":"Placebo With Alhydrogel®","description":"Placebo (buffer with Alhydrogel®) administered by intramuscular injection 2 times with 4 weeks apart"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"24"},{"groupId":"OG002","value":"12"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"15"},{"groupId":"OG002","value":"8"}]}]}]},{"type":"SECONDARY","title":"Immunoglobulin(Ig)G Antibody Concentration","description":"Adjusted geometric mean concentration (GMC)","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Adjusted GMC mcg/mL","timeFrame":"Day 85","groups":[{"id":"OG000","title":"GBS-NN/NN2 With Alhydrogel® 25","description":"GBS-NN/NN2 with Alhydrogel® containing 25 mcg of each GBS-NN and GBS-NN2 administered by intramuscular injection 2 times with 4 weeks apart"},{"id":"OG001","title":"GBS-NN/NN2 With Alhydrogel® 50","description":"GBS-NN/NN2 with Alhydrogel® containing 50mcg of each GBS-NN and GBS-NN2 administered by intramuscular injection 2 times with 4 weeks apart"},{"id":"OG002","title":"Placebo With Alhydrogel®","description":"Placebo (buffer with Alhydrogel®) administered by intramuscular injection 2 times with 4 weeks apart"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"24"},{"groupId":"OG002","value":"12"}]}],"classes":[{"title":"GBS-NN","categories":[{"measurements":[{"groupId":"OG000","value":"15.2","lowerLimit":"11.1","upperLimit":"20.8"},{"groupId":"OG001","value":"17.1","lowerLimit":"12.5","upperLimit":"23.4"},{"groupId":"OG002","value":"0.115","lowerLimit":"0.0746","upperLimit":"0.177"}]}]},{"title":"GBS-NN2","categories":[{"measurements":[{"groupId":"OG000","value":"24.0","lowerLimit":"18.8","upperLimit":"30.8"},{"groupId":"OG001","value":"29.9","lowerLimit":"23.4","upperLimit":"38.3"},{"groupId":"OG002","value":"0.154","lowerLimit":"0.109","upperLimit":"0.216"}]}]}]},{"type":"SECONDARY","title":"Fold Change in Antibody Concentration","description":"Geometric mean fold change in antibody concentration from Day 1 to Day 85 for each group.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Fold change from Day 1 to Day 85","timeFrame":"Day 1 to Day 85","groups":[{"id":"OG000","title":"GBS-NN/NN2 With Alhydrogel® 25","description":"GBS-NN/NN2 with Alhydrogel® containing 25 mcg of each GBS-NN and GBS-NN2 administered by intramuscular injection 2 times with 4 weeks apart"},{"id":"OG001","title":"GBS-NN/NN2 With Alhydrogel® 50","description":"GBS-NN/NN2 with Alhydrogel® containing 50mcg of each GBS-NN and GBS-NN2 administered by intramuscular injection 2 times with 4 weeks apart"},{"id":"OG002","title":"Placebo With Alhydrogel®","description":"Placebo (buffer with Alhydrogel®) administered by intramuscular injection 2 times with 4 weeks apart"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"24"},{"groupId":"OG002","value":"12"}]}],"classes":[{"title":"GBS-NN","categories":[{"measurements":[{"groupId":"OG000","value":"127.707","lowerLimit":"79.310","upperLimit":"205.637"},{"groupId":"OG001","value":"131.526","lowerLimit":"93.987","upperLimit":"184.057"},{"groupId":"OG002","value":"0.951","lowerLimit":"0.791","upperLimit":"1.144"}]}]},{"title":"GBS-NN2","categories":[{"measurements":[{"groupId":"OG000","value":"169.594","lowerLimit":"104.224","upperLimit":"275.964"},{"groupId":"OG001","value":"211.303","lowerLimit":"140.290","upperLimit":"318.260"},{"groupId":"OG002","value":"0.946","lowerLimit":"0.838","upperLimit":"1.068"}]}]}],"analyses":[{"groupIds":["OG000","OG002"],"groupDescription":"Adjusted geometric mean fold increase from Day 1 to Day 85: adjusted geometric mean ratio GBS-NN/NN2 25mcg/placebo","nonInferiorityType":"OTHER","pValue":"<0.0001","statisticalMethod":"ANOVA"},{"groupIds":["OG001","OG002"],"groupDescription":"Adjusted geometric mean fold increase from Day 1 to Day 85: adjusted geometric mean ratio GBS-NN/NN2 50mcg/placebo","nonInferiorityType":"OTHER","pValue":"<0.0001","statisticalMethod":"ANOVA"}]},{"type":"SECONDARY","title":"Seroconversion Rate","description":"4-fold increase in Immunoglobulin(Ig)G antibody concentration","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Day 85","groups":[{"id":"OG000","title":"GBS-NN/NN2 With Alhydrogel® 25","description":"GBS-NN/NN2 with Alhydrogel® containing 25 mcg of each GBS-NN and GBS-NN2 administered by intramuscular injection 2 times with 4 weeks apart"},{"id":"OG001","title":"GBS-NN/NN2 With Alhydrogel® 50","description":"GBS-NN/NN2 with Alhydrogel® containing 50mcg of each GBS-NN and GBS-NN2 administered by intramuscular injection 2 times with 4 weeks apart"},{"id":"OG002","title":"Placebo With Alhydrogel®","description":"Placebo (buffer with Alhydrogel®) administered by intramuscular injection 2 times with 4 weeks apart"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"23"},{"groupId":"OG001","value":"23"},{"groupId":"OG002","value":"12"}]}],"classes":[{"title":"GBS-NN","categories":[{"measurements":[{"groupId":"OG000","value":"23"},{"groupId":"OG001","value":"23"},{"groupId":"OG002","value":"0"}]}]},{"title":"GBS-NN2","categories":[{"measurements":[{"groupId":"OG000","value":"23"},{"groupId":"OG001","value":"23"},{"groupId":"OG002","value":"0"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With an Immune Response to First and Second Doses","description":"Number of participants with Immunoglobulin(Ig)G antibody concentration above thresholds","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Day 29 and Day 85","groups":[{"id":"OG000","title":"GBS-NN/NN2 With Alhydrogel® 25","description":"GBS-NN/NN2 with Alhydrogel® containing 25 mcg of each GBS-NN and GBS-NN2 administered by intramuscular injection 2 times with 4 weeks apart"},{"id":"OG001","title":"GBS-NN/NN2 With Alhydrogel® 50","description":"GBS-NN/NN2 with Alhydrogel® containing 50mcg of each GBS-NN and GBS-NN2 administered by intramuscular injection 2 times with 4 weeks apart"},{"id":"OG002","title":"Placebo With Alhydrogel®","description":"Placebo (buffer with Alhydrogel®) administered by intramuscular injection 2 times with 4 weeks apart"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"24"},{"groupId":"OG002","value":"12"}]}],"classes":[{"title":"GBS-NN Day 29 increase above 1mcg/mL","categories":[{"measurements":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"23"},{"groupId":"OG002","value":"0"}]}]},{"title":"GBS-NN Day 29 increase above 2mcg/mL","categories":[{"measurements":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"20"},{"groupId":"OG002","value":"0"}]}]},{"title":"GBS-NN Day 29 increase above 4mcg/mL","categories":[{"measurements":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"17"},{"groupId":"OG002","value":"0"}]}]},{"title":"GBS-NN Day 29 increase above 8mcg/mL","categories":[{"measurements":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"13"},{"groupId":"OG002","value":"0"}]}]},{"title":"GBS-NN Day 85 increase above 1mcg/mL","categories":[{"measurements":[{"groupId":"OG000","value":"23"},{"groupId":"OG001","value":"23"},{"groupId":"OG002","value":"0"}]}]},{"title":"GBS-NN Day 85 increase above 2mcg/mL","categories":[{"measurements":[{"groupId":"OG000","value":"20"},{"groupId":"OG001","value":"23"},{"groupId":"OG002","value":"0"}]}]},{"title":"GBS-NN Day 85 increase above 4mcg/mL","categories":[{"measurements":[{"groupId":"OG000","value":"20"},{"groupId":"OG001","value":"21"},{"groupId":"OG002","value":"0"}]}]},{"title":"GBS-NN Day 85 increase above 8mcg/mL","categories":[{"measurements":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"20"},{"groupId":"OG002","value":"0"}]}]},{"title":"GBS-NN2 Day 29 increase above 1mcg/mL","categories":[{"measurements":[{"groupId":"OG000","value":"20"},{"groupId":"OG001","value":"22"},{"groupId":"OG002","value":"0"}]}]},{"title":"GBS-NN2 Day 29 increase above 2mcg/mL","categories":[{"measurements":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"22"},{"groupId":"OG002","value":"0"}]}]},{"title":"GBS-NN2 Day 29 increase above 4mcg/mL","categories":[{"measurements":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"18"},{"groupId":"OG002","value":"0"}]}]},{"title":"GBS-NN2 Day 29 increase above 8mcg/mL","categories":[{"measurements":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"18"},{"groupId":"OG002","value":"0"}]}]},{"title":"GBS-NN2 Day 85 increase above 1mcg/mL","categories":[{"measurements":[{"groupId":"OG000","value":"23"},{"groupId":"OG001","value":"23"},{"groupId":"OG002","value":"0"}]}]},{"title":"GBS-NN2 Day 85 increase above 2mcg/mL","categories":[{"measurements":[{"groupId":"OG000","value":"22"},{"groupId":"OG001","value":"22"},{"groupId":"OG002","value":"0"}]}]},{"title":"GBS-NN2 Day 85 increase above 4mcg/mL","categories":[{"measurements":[{"groupId":"OG000","value":"20"},{"groupId":"OG001","value":"22"},{"groupId":"OG002","value":"0"}]}]},{"title":"GBS-NN2 Day 85 increase above 8mcg/mL","categories":[{"measurements":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"22"},{"groupId":"OG002","value":"0"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"0","timeFrame":"85 days","eventGroups":[{"id":"EG000","title":"GBS-NN/NN2 With Alhydrogel® 25","description":"GBS-NN/NN2 with Alhydrogel® containing 25 mcg of each GBS-NN and GBS-NN2 administered by intramuscular injection 2 times with 4 weeks apart","deathsNumAffected":0,"deathsNumAtRisk":24,"seriousNumAffected":0,"seriousNumAtRisk":24,"otherNumAffected":17,"otherNumAtRisk":24},{"id":"EG001","title":"GBS-NN/NN2 With Alhydrogel® 50","description":"GBS-NN/NN2 with Alhydrogel® containing 50 mcg of each GBS-NN and GBS-NN2 administered by intramuscular injection 2 times with 4 weeks apart","deathsNumAffected":0,"deathsNumAtRisk":24,"seriousNumAffected":0,"seriousNumAtRisk":24,"otherNumAffected":15,"otherNumAtRisk":24},{"id":"EG002","title":"Placebo With Alhydrogel®","description":"Placebo (buffer with Alhydrogel®) administered by intramuscular injection 2 times with 4 weeks apart","deathsNumAffected":0,"deathsNumAtRisk":12,"seriousNumAffected":0,"seriousNumAtRisk":12,"otherNumAffected":8,"otherNumAtRisk":12}],"otherEvents":[{"term":"Palpitations","organSystem":"Cardiac disorders","sourceVocabulary":"Medra 22.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":24},{"groupId":"EG001","numAffected":0,"numAtRisk":24},{"groupId":"EG002","numAffected":0,"numAtRisk":12}]},{"term":"Abdominal distension","organSystem":"Gastrointestinal disorders","sourceVocabulary":"Medra 22.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":24},{"groupId":"EG001","numAffected":1,"numAtRisk":24},{"groupId":"EG002","numAffected":0,"numAtRisk":12}]},{"term":"Influenza like illness","organSystem":"General disorders","sourceVocabulary":"Medra 22.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":24},{"groupId":"EG001","numAffected":1,"numAtRisk":24},{"groupId":"EG002","numAffected":0,"numAtRisk":12}]},{"term":"Allergy to animal","organSystem":"Immune system disorders","sourceVocabulary":"Medra 22.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":24},{"groupId":"EG001","numAffected":0,"numAtRisk":24},{"groupId":"EG002","numAffected":0,"numAtRisk":12}]},{"term":"Gastroenteritis viral","organSystem":"Infections and infestations","sourceVocabulary":"Medra 22.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":24},{"groupId":"EG001","numAffected":0,"numAtRisk":24},{"groupId":"EG002","numAffected":1,"numAtRisk":12}]},{"term":"Ligament sprain","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"Medra 22.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":24},{"groupId":"EG001","numAffected":1,"numAtRisk":24},{"groupId":"EG002","numAffected":0,"numAtRisk":12}]},{"term":"Carpal tunnel syndrome","organSystem":"Nervous system disorders","sourceVocabulary":"Medra 22.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":24},{"groupId":"EG001","numAffected":0,"numAtRisk":24},{"groupId":"EG002","numAffected":0,"numAtRisk":12}]},{"term":"Anxiety","organSystem":"Psychiatric disorders","sourceVocabulary":"Medra 22.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":24},{"groupId":"EG001","numAffected":0,"numAtRisk":24},{"groupId":"EG002","numAffected":1,"numAtRisk":12}]},{"term":"Dyspepsia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"Medra 22.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":24},{"groupId":"EG001","numAffected":0,"numAtRisk":24},{"groupId":"EG002","numAffected":0,"numAtRisk":12}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"Medra 22.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":24},{"groupId":"EG001","numAffected":2,"numAtRisk":24},{"groupId":"EG002","numAffected":0,"numAtRisk":12}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"Medra 22.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":24},{"groupId":"EG001","numAffected":1,"numAtRisk":24},{"groupId":"EG002","numAffected":0,"numAtRisk":12}]},{"term":"Pain","organSystem":"General disorders","sourceVocabulary":"Medra 22.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":24},{"groupId":"EG001","numAffected":0,"numAtRisk":24},{"groupId":"EG002","numAffected":1,"numAtRisk":12}]},{"term":"Pyrexia","organSystem":"General disorders","sourceVocabulary":"Medra 22.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":24},{"groupId":"EG001","numAffected":0,"numAtRisk":24},{"groupId":"EG002","numAffected":0,"numAtRisk":12}]},{"term":"Influenza","organSystem":"Infections and infestations","sourceVocabulary":"Medra 22.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":24},{"groupId":"EG001","numAffected":0,"numAtRisk":24},{"groupId":"EG002","numAffected":0,"numAtRisk":12}]},{"term":"Lower respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"Medra 22.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":24},{"groupId":"EG001","numAffected":0,"numAtRisk":24},{"groupId":"EG002","numAffected":0,"numAtRisk":12}]},{"term":"Nasopharyngitis","organSystem":"Infections and infestations","sourceVocabulary":"Medra 22.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":24},{"groupId":"EG001","numAffected":2,"numAtRisk":24},{"groupId":"EG002","numAffected":2,"numAtRisk":12}]},{"term":"Pharyngitis","organSystem":"Infections and infestations","sourceVocabulary":"Medra 22.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":24},{"groupId":"EG001","numAffected":0,"numAtRisk":24},{"groupId":"EG002","numAffected":0,"numAtRisk":12}]},{"term":"Tonsillitis","organSystem":"Infections and infestations","sourceVocabulary":"Medra 22.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":24},{"groupId":"EG001","numAffected":1,"numAtRisk":24},{"groupId":"EG002","numAffected":0,"numAtRisk":12}]},{"term":"Upper respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"Medra 22.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":24},{"groupId":"EG001","numAffected":1,"numAtRisk":24},{"groupId":"EG002","numAffected":0,"numAtRisk":12}]},{"term":"Urinary tract infection","organSystem":"Infections and infestations","sourceVocabulary":"Medra 22.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":24},{"groupId":"EG001","numAffected":1,"numAtRisk":24},{"groupId":"EG002","numAffected":0,"numAtRisk":12}]},{"term":"Viral infection","organSystem":"Infections and infestations","sourceVocabulary":"Medra 22.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":24},{"groupId":"EG001","numAffected":0,"numAtRisk":24},{"groupId":"EG002","numAffected":1,"numAtRisk":12}]},{"term":"Vulvovaginal candidiasis","organSystem":"Infections and infestations","sourceVocabulary":"Medra 22.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":24},{"groupId":"EG001","numAffected":0,"numAtRisk":24},{"groupId":"EG002","numAffected":0,"numAtRisk":12}]},{"term":"Post-traumatic neck syndrome","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"Medra 22.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":24},{"groupId":"EG001","numAffected":0,"numAtRisk":24},{"groupId":"EG002","numAffected":0,"numAtRisk":12}]},{"term":"Arthralgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"Medra 22.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":24},{"groupId":"EG001","numAffected":1,"numAtRisk":24},{"groupId":"EG002","numAffected":0,"numAtRisk":12}]},{"term":"Back pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"Medra 22.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":24},{"groupId":"EG001","numAffected":0,"numAtRisk":24},{"groupId":"EG002","numAffected":0,"numAtRisk":12}]},{"term":"Musculoskeletal chest pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"Medra 22.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":24},{"groupId":"EG001","numAffected":0,"numAtRisk":24},{"groupId":"EG002","numAffected":0,"numAtRisk":12}]},{"term":"Neck pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"Medra 22.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":24},{"groupId":"EG001","numAffected":0,"numAtRisk":24},{"groupId":"EG002","numAffected":1,"numAtRisk":12}]},{"term":"Pain in extremity","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"Medra 22.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":24},{"groupId":"EG001","numAffected":1,"numAtRisk":24},{"groupId":"EG002","numAffected":0,"numAtRisk":12}]},{"term":"Dizziness","organSystem":"Nervous system disorders","sourceVocabulary":"Medra 22.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":24},{"groupId":"EG001","numAffected":0,"numAtRisk":24},{"groupId":"EG002","numAffected":1,"numAtRisk":12}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"Medra 22.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":9,"numAtRisk":24},{"groupId":"EG001","numAffected":5,"numAtRisk":24},{"groupId":"EG002","numAffected":5,"numAtRisk":12}]},{"term":"Lethargy","organSystem":"Nervous system disorders","sourceVocabulary":"Medra 22.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":24},{"groupId":"EG001","numAffected":1,"numAtRisk":24},{"groupId":"EG002","numAffected":0,"numAtRisk":12}]},{"term":"Migraine","organSystem":"Nervous system disorders","sourceVocabulary":"Medra 22.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":24},{"groupId":"EG001","numAffected":1,"numAtRisk":24},{"groupId":"EG002","numAffected":0,"numAtRisk":12}]},{"term":"Sleep disorder","organSystem":"Psychiatric disorders","sourceVocabulary":"Medra 22.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":24},{"groupId":"EG001","numAffected":1,"numAtRisk":24},{"groupId":"EG002","numAffected":0,"numAtRisk":12}]},{"term":"Dysmenorrhoea","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"Medra 22.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":24},{"groupId":"EG001","numAffected":1,"numAtRisk":24},{"groupId":"EG002","numAffected":0,"numAtRisk":12}]},{"term":"Hypomenorrhoea","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"Medra 22.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":24},{"groupId":"EG001","numAffected":0,"numAtRisk":24},{"groupId":"EG002","numAffected":1,"numAtRisk":12}]},{"term":"Cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"Medra 22.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":24},{"groupId":"EG001","numAffected":0,"numAtRisk":24},{"groupId":"EG002","numAffected":0,"numAtRisk":12}]},{"term":"Oropharyngeal pain","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"Medra 22.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":24},{"groupId":"EG001","numAffected":2,"numAtRisk":24},{"groupId":"EG002","numAffected":1,"numAtRisk":12}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictiveAgreement":false},"pointOfContact":{"title":"Dr Per Fischer","organization":"MinervaX ApS","email":"pbf@minervax.com","phone":"+45 20 25 20 38"}}},"documentSection":{"largeDocumentModule":{"largeDocs":[{"typeAbbrev":"Prot_SAP","hasProtocol":true,"hasSap":true,"hasIcf":false,"label":"Study Protocol and Statistical Analysis Plan","date":"2019-01-02","uploadDate":"2020-11-30T09:12","filename":"Prot_SAP_000.pdf","size":2512770}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-11-09"},"conditionBrowseModule":{"meshes":[{"id":"D013290","term":"Streptococcal Infections"}],"ancestors":[{"id":"D016908","term":"Gram-Positive Bacterial Infections"},{"id":"D001424","term":"Bacterial Infections"},{"id":"D001423","term":"Bacterial Infections and Mycoses"},{"id":"D007239","term":"Infections"}]}},"hasResults":true}